{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:59:38Z","timestamp":1780469978943,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.rdc.2021.07.014","type":"journal-article","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T22:15:52Z","timestamp":1630534552000},"page":"737-755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Juvenile Localized Scleroderma"],"prefix":"10.1016","volume":"47","author":[{"given":"Natalia","family":"Vasquez-Canizares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne C.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2021.07.014_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jpeds.2021.01.068","article-title":"Morbidity and Disability in Juvenile Localized Scleroderma: The Case for Early Recognition and Systemic Immunosuppressive Treatment","volume":"234","author":"Li","year":"2021","journal-title":"J\u00a0Pediatr"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.014_bib2","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/art.21264","article-title":"Localized scleroderma in childhood is not just a skin disease","volume":"52","author":"Zulian","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2021.07.014_bib3","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3389\/fimmu.2019.00908","article-title":"Immunopathogenesis of Pediatric Localized Scleroderma","volume":"10","author":"Torok","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.rdc.2021.07.014_bib4","first-page":"73","article-title":"The epidemiology of morphea (localized scleroderma) in Olmstead County 1960-1993","volume":"24","author":"Peterson","year":"1997","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.014_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/acr2.1019","article-title":"Baseline description of the juvenile localized scleroderma subgroup from the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry","volume":"1","author":"Wu","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.014_bib6","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1001\/archdermatol.2009.79","article-title":"Distinct Autoimmune Syndromes in Morphea","volume":"145","author":"Leitenberger","year":"2009","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.014_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/bjd.15001","article-title":"The molecular pathogenesis of morphoea: from genetics to future treatment targets","volume":"177","author":"Saracino","year":"2017","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.014_bib8","first-page":"208","article-title":"Scleroderma with an update about clinico-pathological correlation","volume":"153","author":"Rongioletti","year":"2018","journal-title":"G\u00a0Ital Dermatol Venereol"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.014_bib9","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00403-019-01991-0","article-title":"MicroRNA in localized scleroderma: a review of literature","volume":"312","author":"Wolska-Gawron","year":"2020","journal-title":"Arch Dermatol Res"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.014_bib10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jid.2018.09.025","article-title":"Identifying the Signature Immune Phenotypes Present in Pediatric Localized Scleroderma","volume":"139","author":"Mirizio","year":"2019","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.rdc.2021.07.014_bib11","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jaut.2019.04.008","article-title":"The identification of CCL18 as biomarker of disease activity in localized scleroderma","volume":"10","author":"Mertens","year":"2019","journal-title":"J\u00a0Autoimmun"},{"issue":"609","key":"10.1016\/j.rdc.2021.07.014_bib12","doi-asserted-by":"crossref","first-page":"eaaz0274","DOI":"10.1126\/scisignal.aaz0274","article-title":"The human secretome","volume":"12","author":"Uhl\u00e9n","year":"2019","journal-title":"Sci Signal"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.014_bib13","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/bjd.17352","article-title":"Differential expression of secreted factors SOSTDC1 and ADAMTS8 cause profibrotic changes in linear morphoea fibroblasts","volume":"180","author":"Badshah","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rdc.2021.07.014_bib14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-019-1015-7","article-title":"Linear scleroderma \u201cen coup de sabre\u201d with extensive brain involvement\u2014Clinicopathologic correlations and response to anti-Interleukin-6 therapy","volume":"14","author":"Magro","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.rdc.2021.07.014_bib15","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/01.dad.0000183679.40184.23","article-title":"Alterations of Basemement Membrane Zone and Cutaneous Microvasculature in Morphea and Extragenital Lichen Sclerosus","volume":"27","author":"Kowalewski","year":"2005","journal-title":"Am J Dermatopathol"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.014_bib16","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.autrev.2017.05.024","article-title":"The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review","volume":"16","author":"Mostmans","year":"2017","journal-title":"Autoimmun Rev"},{"issue":"1 Pt 1","key":"10.1016\/j.rdc.2021.07.014_bib17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0190-9622(00)90010-0","article-title":"Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma","volume":"42","author":"Yamane","year":"2000","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2021.07.014_bib18","first-page":"72","article-title":"Exploring the Use of Von Willebrand Factor as a Disease Biomarker in a Cohort of Patients with Juvenile Scleroderma: A Pilot Study [abstract]","author":"Vasquez-Canizares","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.014_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2020.5809","article-title":"An Evaluation of the Performance of Current Morphea Subtype Classifications","volume":"157","author":"Prasad","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.rdc.2021.07.014_bib20","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaad.2012.04.003","article-title":"Coexistence of lichen sclerosus and morphea: a retrospective analysis of 472 patients with localized scleroderma from a German tertiary referral center","volume":"67","author":"Kreuter","year":"2012","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.rdc.2021.07.014_bib21","first-page":"171","article-title":"Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases","volume":"13","author":"Marzano","year":"2003","journal-title":"Eur J Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.014_bib22","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjd.13514","article-title":"Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease","volume":"172","author":"Mertens","year":"2015","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.014_bib23","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jaad.2008.05.005","article-title":"Pediatric morphea (localized scleroderma): review of 136 patients","volume":"59","author":"Christen-Zaech","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.014_bib24","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12969-018-0295-0","article-title":"Multi-centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management","volume":"16","author":"Lythgoe","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.014_bib25","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/bjd.12758","article-title":"Risk factors for morphoea disease severity: a retrospective review of 114 paediatric patients","volume":"170","author":"Pequet","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rdc.2021.07.014_bib26","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1093\/rheumatology\/kei251","article-title":"Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study","volume":"45","author":"Zulian","year":"2006","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.014_bib27","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3899\/jrheum.171381","article-title":"New Features for Measuring Disease Activity in Pediatric Localized Scleroderma","volume":"45","author":"Li","year":"2018","journal-title":"J\u00a0Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.014_bib28","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/acr.23101","article-title":"Predictors of Longitudinal Quality of Life in Juvenile Localized Scleroderma","volume":"69","author":"Ardalan","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2021.07.014_bib29","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab238","article-title":"Extracutaneous Involvement Is Common and Associated with Prolonged Disease Activity and Greater Impact in Juvenile Localized Scleroderma","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2021.07.014_bib30","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1212\/01.wnl.0000334474.88923.e3","article-title":"Neurologic manifestations of localized scleroderma. A case report and literature review","volume":"71","author":"Kister","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.rdc.2021.07.014_bib31","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1212\/01.WNL.0000124518.25087.18","article-title":"Neuroimaging findings in scleroderma en coup de sabre","volume":"62","author":"Appenzeller","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.rdc.2021.07.014_bib32","doi-asserted-by":"crossref","first-page":"567","DOI":"10.5152\/eurjrheum.2019.19147","article-title":"Characteristics of coexisting localized scleroderma and inflammatory arthritis","volume":"7","author":"Reiff","year":"2020","journal-title":"Eur J Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.014_bib33","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jaad.2018.03.005","article-title":"Inflammatory arthritis in pediatric patients with morphea","volume":"79","author":"Kashem","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.014_bib34","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1007\/s00247-018-4177-x","article-title":"The central nervous system manifestations of localized craniofacial scleroderma: a study of 10 cases and literature review","volume":"48","author":"Maloney","year":"2018","journal-title":"Pediatr Radiol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.014_bib35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.survophthal.2016.03.009","article-title":"Ophthalmological manifestations of Parry-Romberg syndrome","volume":"61","author":"Bucher","year":"2016","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.rdc.2021.07.014_bib36","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00006534-199005000-00001","article-title":"Clinical and ultrastructural studies of Romberg's hemifacial atrophy","volume":"85","author":"Pensler","year":"1990","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.rdc.2021.07.014_bib37","doi-asserted-by":"crossref","first-page":"849","DOI":"10.7326\/0003-4819-104-6-849","article-title":"Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities","volume":"104","author":"Falanga","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.rdc.2021.07.014_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/archderm.1948.01520200004001","article-title":"Linear scleroderma; association with abnomalities","volume":"58","author":"Rubin","year":"1948","journal-title":"Arch Derm Syphilol"},{"key":"10.1016\/j.rdc.2021.07.014_bib39","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.3899\/jrheum.080098","article-title":"Serum Autoantibodies and Their Clinical Associations in Patients with Childhood- and Adult-Onset Linear Scleroderma. A Single-Center Study","volume":"35","author":"Arkachaisri","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.014_bib40","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.jaad.2019.01.050","article-title":"Linear morphea: Clinical characteristics, disease course, and treatment of the Morphea in Adults and Children cohort","volume":"80","author":"Kunzler","year":"2019","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.014_bib41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2133.2008.08647.x","article-title":"Linear morphoea follows Blaschko's lines","volume":"159","author":"Weibel","year":"2008","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.014_bib42","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/bjd.12606","article-title":"Short- and long-term outcome of linear morphoea in children","volume":"169","author":"Piram","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.rdc.2021.07.014_bib43","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/art.1780390624","article-title":"Childhood-onset scleroderma","volume":"39","author":"Vancheeswaran","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.rdc.2021.07.014_bib44","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jaad.2015.09.069","article-title":"Characteristics and treatment of adult-onset linear morphea: A retrospective cohort study of 61 patients at 3 tertiary care centers","volume":"74","author":"Mazori","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.014_bib45","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2340\/00015555-2920","article-title":"Localized Scleroderma of the Head and Face Area: A Retrospective Cross-sectional Study of 96 Patients from 5 German Tertiary Referral Centres","volume":"98","author":"Kreuter","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.rdc.2021.07.014_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00234-014-1448-6","article-title":"CNS imaging findings associated with Parry-Romberg syndrome and en coup de sabre: correlation to dermatologic and neurologic abnormalities","volume":"57","author":"Doolittle","year":"2015","journal-title":"Neuroradiology"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.014_bib47","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/00207454.2016.1244823","article-title":"Neurological abnormalities in localized scleroderma of the face and head: a case series study for evaluation of imaging findings and clinical course","volume":"127","author":"Lis-Swiety","year":"2017","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.rdc.2021.07.014_bib48","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/978-1-4615-4857-7_14","article-title":"Linear scleroderma en Coup de Sabre. Relationship with progressive facial hemiatrophy (PFH)","volume":"455","author":"Blaszczyk","year":"1999","journal-title":"Adv Exp Med Biol"},{"issue":"9","key":"10.1016\/j.rdc.2021.07.014_bib49","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00431-015-2532-6","article-title":"Overlap between linear scleroderma, progressive facial hemiatrophy and immune-inflammatory encephalitis in a paediatric cohort","volume":"174","author":"De Somer","year":"2015","journal-title":"Eur J Pediatr"},{"issue":"11","key":"10.1016\/j.rdc.2021.07.014_bib50","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/0883073820931253","article-title":"Unilateral Neuroimaging Findings in Pediatric Craniofacial Scleroderma: Parry-Romberg Syndrome and En Coup de Sabre","volume":"35","author":"Seese","year":"2020","journal-title":"J\u00a0Child Neurol"},{"issue":"6","key":"10.1016\/j.rdc.2021.07.014_bib51","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/pde.12001","article-title":"A\u00a0significant proportion of children with morphea en coup de sabre and Parry-Romberg syndrome have neuroimaging findings","volume":"29","author":"Chiu","year":"2012","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.rdc.2021.07.014_bib52","first-page":"343","article-title":"Scleroderma in childhood","volume":"20","author":"Kornreich","year":"1977","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.014_bib53","first-page":"73","article-title":"Autoantibodies in Parry-Romberg syndrome: a serologic study of 14 patients","volume":"22","author":"Garcia-de la Torre","year":"1995","journal-title":"J\u00a0Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2021.07.014_bib54","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.3899\/jrheum.081284","article-title":"The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures","volume":"36","author":"Arkachaisri","year":"2009","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.rdc.2021.07.014_bib55","first-page":"72","article-title":"Capturing the Range of Disease Involvement in Localized Scleroderma: The Total Morbidity Score [abstract]","author":"Li","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.014_bib56","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2018-214697","article-title":"Consensus-based recommendations for the management of juvenile localised scleroderma","volume":"78","author":"Zulian","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.014_bib57","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3899\/jrheum.190311","article-title":"Initial Results from a Pilot Comparative Effectiveness Study of 3 Methotrexate-based Consensus Treatment Plans for Juvenile Localized Scleroderma","volume":"47","author":"Li","year":"2020","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2021.07.014_bib58","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/jdv.13790","article-title":"A\u00a0systematic review of tools for determining activity of localized scleroderma in paediatric and adult patients","volume":"31","author":"Lis-Swiety","year":"2017","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.rdc.2021.07.014_bib59","first-page":"CD005027","article-title":"Interventions for morphea","volume":"7","author":"Albuquerque","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.014_bib60","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/acr.21687","article-title":"Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma","volume":"64","author":"Li","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.rdc.2021.07.014_bib61","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2340\/00015555-2411","article-title":"Drug Survival and Predictors of Drug Survival for Methotrexate Treatment in a Retrospective Cohort of Adult Patients with Localized Scleroderma","volume":"96","author":"Mertens","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.rdc.2021.07.014_bib62","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.autrev.2018.02.004","article-title":"Disease course and long-term outcome of juvenile localized scleroderma: Experience from a single pediatric rheumatology Centre and literature review","volume":"17","author":"Martini","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.014_bib63","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1093\/rheumatology\/keaa392","article-title":"Mycophenolate mofetil for methotrexate-resistant juvenile localized scleroderma","volume":"60","author":"Martini","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2021.07.014_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamadermatol.2020.0035","article-title":"Evaluation of the Effectiveness and Tolerability of Mycophenolate Mofetil and Mycophenolic Acid for the Treatment of Morphea","volume":"156","author":"Arthur","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"3","key":"10.1016\/j.rdc.2021.07.014_bib65","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5301\/jsrd.5000259","article-title":"Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma patients","volume":"2","author":"Foeldvari","year":"2017","journal-title":"J\u00a0Scleroderma Relat Disord"},{"issue":"4","key":"10.1016\/j.rdc.2021.07.014_bib66","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.semarthrit.2020.03.020","article-title":"Abatacept in the treatment of localized scleroderma: A pediatric case series and systematic literature review","volume":"50","author":"Kalampokis","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.rdc.2021.07.014_bib67","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1093\/rheumatology\/keaa873","article-title":"Preliminary Evidence on Abatacept Safety and Efficacy in Refractory Juvenile Localized Scleroderma","volume":"60","author":"Li","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.rdc.2021.07.014_bib68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2174\/18743129014090100030","article-title":"A\u00a0Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide","volume":"9","author":"Ferguson","year":"2015","journal-title":"Open Rheumatol J"},{"issue":"7","key":"10.1016\/j.rdc.2021.07.014_bib69","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.jid.2019.12.019","article-title":"Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea","volume":"140","author":"Damsky","year":"2020","journal-title":"J\u00a0Invest Dermatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X2101108X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X2101108X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T11:21:43Z","timestamp":1760181703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X2101108X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S0889857X2101108X"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2021.07.014","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Juvenile Localized Scleroderma","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2021.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}